Skip to main content
Addgene

pLV-H2B-iRFP670-p2a-YFP-Rb-IRES-blasticidin
(Plasmid #223962)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 223962 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pLV-EF1a-IRES-blasticidin
  • Vector type
    Mammalian Expression
  • Selectable markers
    Blasticidin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    30°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    H2B-iRFP670-p2a-YFP-Rb
  • Alt name
    H2B
  • Alt name
    Rb
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    4890
  • Entrez Gene
    RB1 (a.k.a. OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb, pp110)
  • Entrez Gene
    H2B
  • Promoter EF-1a
  • Tags / Fusion Proteins
    • iRFP670
    • YFP

Cloning Information

  • Cloning method Gibson Cloning
  • 5′ sequencing primer For H2B-iRFP670: catttcaggtgtcgtgagggatccgccacc; For YFP-Rb: CCGGTCCTTCTAAAGGTGAAGAATTATTCACTGGTGTTGT
  • 3′ sequencing primer For H2B-iRFP670: acctttagaaggaccgggattttcttccac; For YFP-Rb: cggccgccctcgaggaattcTTATTTCTCTTCCTTGTTTGAGGTATCC
    • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLV-H2B-iRFP670-p2a-YFP-Rb-IRES-blasticidin was a gift from Hee Won Yang (Addgene plasmid # 223962 ; http://n2t.net/addgene:223962 ; RRID:Addgene_223962)

  • For your References section:

    Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, Chandarlapaty S, Yang HW. Cell Rep. 2023 Nov 28;42(11):113198. doi: 10.1016/j.celrep.2023.113198. Epub 2023 Oct 21. 10.1016/j.celrep.2023.113198 PubMed 37865915
Related items: